Researchers at University of Oxford have been awarded funding by Cancer Research UK to develop a vaccine to prevent ovarian cancer. The team will receive up to £600,000 (US$784,000) for the study over the next 3 years to support lab research on Ovarianvax.
Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway are widely used in cancer immunotherapy, but poor tissue distribution or immune-related adverse events often limit their application.
At this week’s American Society for Radiation Oncology meeting, scientists from The University of Texas MD Anderson Cancer Center reported the discovery and preclinical evaluation of CD47-LLO, a novel microbial-inspired antibody-drug conjugate (ADC) for the treatment of cancer.
Alentis Therapeutics AG has obtained IND clearance from the FDA for ALE.P02, an anti-Claudin-1 (CLDN1) antibody-drug conjugate (ADC) with a tubulin inhibitor payload.
Akeso Pharmaceuticals Inc. scored two approvals from China’s National Medical Products Administration on Sept. 30 before the long Labor Day holiday – one for its PCSK9 inhibitor, ebronucimab, and the second to expand use of PD-1/CTLA4 bispecific antibody cadonilimab in unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, marking the second indication for cadonilimab in China.
Spima Therapeutics SAS has announced its launch with a focus on developing innovative peptide-based immunotherapies for difficult-to-reach targets, especially protein-protein interactions.
Cartherics Pty Ltd. has raised over its target of AU$15 million (US$10.3 million) in an oversubscribed private financing round. Funding will support a clinical trial for CTH-401, the company’s lead cell therapy for ovarian cancer, and expand its pipeline to include other diseases.
Ichnos Glenmark Innovation (IGI) has announced a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI) to evaluate IGI’s selective, orally active Casitas B-lineage lymphoma b (Cbl-b) inhibitor GRC-65327.
Suzhou Ribo Life Science Co. Ltd. recently reported on the development and preclinical characterization of a novel blood-brain barrier (BBB)-penetrating oligonucleotide drug, RBD-8088, for the treatment of glioblastoma.
The FDA’s Oncologic Drugs Advisory Committee (ODAC) met for what chairperson Christopher Lieu called, at the end, “an incredibly long day” to decide whether approval of immune checkpoint inhibitors should be restricted in accordance with expression levels of PD-L1.
RSS
